AROC Stock Overview
A vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AroCell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.42 |
| 52 Week High | kr0.65 |
| 52 Week Low | kr0.30 |
| Beta | 1.08 |
| 1 Month Change | -2.53% |
| 3 Month Change | 13.98% |
| 1 Year Change | -27.15% |
| 3 Year Change | -91.94% |
| 5 Year Change | -84.00% |
| Change since IPO | -87.15% |
Recent News & Updates
Recent updates
Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?
Apr 20
Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)
Feb 27At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?
Nov 07We Think AroCell (STO:AROC) Can Afford To Drive Business Growth
Aug 10AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans
Apr 18We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely
Jan 03
Shareholder Returns
| AROC | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 5.5% | 0.4% | -1.3% |
| 1Y | -27.1% | 1.1% | 13.4% |
Return vs Industry: AROC underperformed the Swedish Life Sciences industry which returned 1.1% over the past year.
Return vs Market: AROC underperformed the Swedish Market which returned 13.4% over the past year.
Price Volatility
| AROC volatility | |
|---|---|
| AROC Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: AROC has not had significant price volatility in the past 3 months.
Volatility Over Time: AROC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 22 | Anders Hultman | www.arocell.com |
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever.
AroCell AB (publ) Fundamentals Summary
| AROC fundamental statistics | |
|---|---|
| Market cap | kr97.67m |
| Earnings (TTM) | -kr56.13m |
| Revenue (TTM) | kr44.79m |
2.2x
P/S Ratio-1.7x
P/E RatioIs AROC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AROC income statement (TTM) | |
|---|---|
| Revenue | kr44.79m |
| Cost of Revenue | kr44.16m |
| Gross Profit | kr627.00k |
| Other Expenses | kr56.76m |
| Earnings | -kr56.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 1.40% |
| Net Profit Margin | -125.33% |
| Debt/Equity Ratio | 0% |
How did AROC perform over the long term?
See historical performance and comparison